Targets › MULTIPLE
3 programs from 2 companies in 5 trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Oncology; next expected readout Feb 2027.
Open in Phaseline: the race on MULTIPLE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City of Hope Medical Center | Mitomycin DNA alkylating agent | MULTIPLE | Phase 3 | Metastatic Appendix Carcinoma; Lung Non-Small Cell Carcinoma; Clinical Stage IV Gastric Cancer AJCC v8 | Oct 2027 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Bleomycin DNA-damaging chemotherapeutic agent used with electrochemotherapy (ECT) | MULTIPLE | Phase 2 | Paget Disease of the Vulva | Feb 2027 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Cisplatin Platinum-based DNA-damaging chemotherapeutic agent used with electrochemotherapy (ECT) | MULTIPLE | Phase 2 | Paget Disease of the Vulva | Feb 2027 |
Paget Disease of the Vulva (2) Metastatic Appendix Carcinoma (1) Lung Non-Small Cell Carcinoma (1) Clinical Stage IV Gastric Cancer AJCC v8 (1)
small molecule (3)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) City of Hope Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.